Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy.

Authors

null

Saisha Abhay Nalawade

Baylor College of Medicine, Houston, TX

Saisha Abhay Nalawade , Paul Shafer , Pradip Bajgain , Katie McKenna , Arushana Ali , Lauren Kelly , Jarrett Joubert , Norihiro Watanabe , Ann Leen , Robin Parihar , Juan Fernando Vera Valdes , Valentina Hoyos Velez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1032)

DOI

10.1200/JCO.2021.39.15_suppl.1032

Abstract #

1032

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Effect of dendritic cells (DC) transduced with chimeric antigen receptor (CAR) on CAR T-cell cytotoxicity.

Effect of dendritic cells (DC) transduced with chimeric antigen receptor (CAR) on CAR T-cell cytotoxicity.

First Author: Hyung Chan Suh

Poster

2020 ASCO Virtual Scientific Program

Selective targeting of HER2-overexpressing solid tumors with a next-generation CAR-T cell therapy.

Selective targeting of HER2-overexpressing solid tumors with a next-generation CAR-T cell therapy.

First Author: Jenny Mu

Poster

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Biological characteristics and prognostic value of Tfh-like cells in the tumor tissue of breast cancer.

Biological characteristics and prognostic value of Tfh-like cells in the tumor tissue of breast cancer.

First Author: Linxiaoxi Ma

Poster

2018 ASCO Annual Meeting

GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers.

GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers.

First Author: Jonathan Back